Chad Costley | Chief Executive Officer
BlueWillow Biologics, Inc.

Chad Costley, Chief Executive Officer, BlueWillow Biologics, Inc.

Dr. Costley oversees the strategy and operations for BlueWillow Biologics, a clinical-stage vaccine company that has developed the only intranasal adjuvant platform currently available with established human immunogenicity and safety data. He has held the CEO role at the company since 2021 after previously serving on the board of directors for several years. Dr. Costley is also a clinician who earned his MD degree and completed residency training at the University of Michigan. He later earned his MBA from Emory University. He's served as the managing director for two private investment funds and on the board of directors of several private companies.


Day 1 - Tuesday 29th October @ 15:30

NE01 Intranasal Adjuvant: Phase 1 H5N1 Influenza Immunogenicity and Safety Results

last published: 10/Jun/24 12:45 GMT

back to speakers